TY - JOUR
T1 - Drugs in Focus
T2 - Domperidone
AU - Puoti, Maria Giovanna
AU - Assa, Amit
AU - Benninga, Marc
AU - Broekaert, Ilse Julia
AU - Carpi, Francisco Javier Martin
AU - Deganello Saccomani, Marco
AU - Dolinsek, Jernej
AU - Homan, Matjaz
AU - Mas, Emmanuel
AU - Miele, Erasmo
AU - Tzivinikos, Christos
AU - Thomson, Mike
AU - Borrelli, Osvaldo
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/8/1
Y1 - 2023/8/1
N2 - Domperidone is a peripheral dopamine-2 receptor antagonist with prokinetic and antiemetic properties. Its prokinetic effects are mainly manifest in the upper gastrointestinal (GI) tract. Currently its use is restricted to relief of nausea and vomiting in children older than 12 years for a short period of time. However, among (pediatric) gastroenterologists, domperidone is also used outside its authorized indication ("off label") for treatment of symptoms associated with gastro-esophageal reflux disease, dyspepsia, and gastroparesis. Little is known about its efficacy in the treatment of GI motility disorders in children and controversial data have emerged in the pediatric literature. As its use is off label, appropriate knowledge of its efficacy is helpful to support an "off label/on evidence" prescription. Based on this, the purpose of this review is to summarize all evidence on the efficacy of domperidone for the treatment of GI disorders in infants and children and to report an overview of its pharmacological properties and safety profile.
AB - Domperidone is a peripheral dopamine-2 receptor antagonist with prokinetic and antiemetic properties. Its prokinetic effects are mainly manifest in the upper gastrointestinal (GI) tract. Currently its use is restricted to relief of nausea and vomiting in children older than 12 years for a short period of time. However, among (pediatric) gastroenterologists, domperidone is also used outside its authorized indication ("off label") for treatment of symptoms associated with gastro-esophageal reflux disease, dyspepsia, and gastroparesis. Little is known about its efficacy in the treatment of GI motility disorders in children and controversial data have emerged in the pediatric literature. As its use is off label, appropriate knowledge of its efficacy is helpful to support an "off label/on evidence" prescription. Based on this, the purpose of this review is to summarize all evidence on the efficacy of domperidone for the treatment of GI disorders in infants and children and to report an overview of its pharmacological properties and safety profile.
KW - antiemetic
KW - children
KW - domperidone
KW - infants
KW - motility GI disorders
KW - prokinetics
UR - http://www.scopus.com/inward/record.url?scp=85165521477&partnerID=8YFLogxK
U2 - 10.1097/MPG.0000000000003822
DO - 10.1097/MPG.0000000000003822
M3 - Review article
C2 - 37159421
AN - SCOPUS:85165521477
SN - 0277-2116
VL - 77
SP - E13-E22
JO - Journal of Pediatric Gastroenterology and Nutrition
JF - Journal of Pediatric Gastroenterology and Nutrition
IS - 2
ER -